Christopher Knight

Christopher Knight

Auto-generated profile, based on publicly available information

Christopher Knight

RTI Health Solutions, Manchester, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Health Technology Assessment
Verified
Journal Article
Closed access
PDF file
JGJ Greenhalgh
J Greenhalgh
CKC Knight
C Knight
DHDaniel Hind
Daniel Hind
CBC Beverley
C Beverley
SWS Walters
S Walters
Health Technology Assessment Volume: 9, Issue: 9, Published in March 2005

1 May 2018 in Value in Health
Verified
Journal Article
Closed access
IPIsobel Pearson
Isobel Pearson
BRBen Rothwell
Ben Rothwell
AOAndrew Olaye
Andrew Olaye
CKChristopher Knight
Christopher Knight

4 February 2019 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
SZSantiago Zuluaga-Sanchez
Santiago Zuluaga-Sanchez
MTMegan Teynor
Megan Teynor
CKChristopher Knight
Christopher Knight
RTRobin Thompson
Robin Thompson
TLThomas Lundqvist
Thomas Lundqvist
ALAndrew J. Lloyd
Andrew J. Lloyd
Spinal muscular atrophy is a rare neuromuscular disorder with a spectrum of severity related to age at onset and the number of SMN2 gene copies. Infantile-onset (≤ 6 months of age) is the most severe spinal muscular atrophy and is the leading monogenetic cause of infant mortality; patients with later-onset (> 6 months of age) spinal muscular atrophy can survive into adulthood. Nusinersen is a new treatment for spinal muscular atrophy.

20 January 2014 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
MCMatthew Richard Cawson
Matthew Richard Cawson
SMStephen Andrew Mitchell
Stephen Andrew Mitchell
CKChris Knight
Chris Knight
HWHenry Wildey
Henry Wildey
DSDean Spurden
Dean Spurden
MOMichelle Elaine Orme
Michelle Elaine Orme
Background: An updated economic evaluation was conducted to compare the cost-effectiveness of the four tumour necrosis factor (TNF)-α inhibitors adalimumab, etanercept, golimumab and infliximab in active, progressive psoriatic arthritis (PsA) where response to standard treatment has been inadequate.Methods: A systematic review was conducted to identify relevant, recently published studies and the new trial data were synthesised, via a Bayesian network meta-analysis (NMA), to estimate the relative efficacy of the TNF-α inhibitors in terms of Psoriatic Arthritis Response Criteria (PsARC) response, Health Assessment Questionnaire (HAQ) scores and Psoriasis Area and Severity Index (PASI). A previously developed economic model was updated with the new meta-analysis results and current cost data. The model was adapted to delineate patients by PASI 50%, 75% and 90% response rates to differentiate between psoriasis outcomes.Results: All four licensed TNF-α inhibitors were significantly more effective than placebo in achieving PsARC response in patients with active PsA. Adalimumab, etanercept and infliximab were significantly more effective than placebo in improving HAQ scores in patients who had achieved a PsARC response and in improving HAQ scores in PsARC non-responders. In an analysis using 1,000 model simulations, on average etanercept was the most cost-effective treatment and, at the National Institute for Health and Care Excellence willingness-to-pay threshold of between £20,000 to £30,000, etanercept is the preferred option.Conclusions: The economic analysis agrees with the conclusions from the previous models, in that biologics are shown to be cost-effective for treating patients with active PsA compared with the conventional management strategy. In particular, etanercept is cost-effective compared with the other biologic treatments.

20 January 2009 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
CKChris Knight
Chris Knight
ADAnne Møller Danø
Anne Møller Danø
TKTessa Kennedy-Martin
Tessa Kennedy-Martin

23 March 2009 in Haemophilia
Verified
Journal Article
Closed access
PDF file
CKC. Knight
C. Knight
ADA. M. Danø
A. M. Danø
TKT. Kennedy‐Martin
T. Kennedy‐Martin